ReviewCancers2021

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.

Marie Decraecker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.